(4-(4-fluorophenoxy)phenyl)hydrazine | 754177-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(4-fluorophenoxy)phenyl)hydrazine
• 英文别名: Hydrazine, [4-(4-fluorophenoxy)phenyl]-；[4-(4-fluorophenoxy)phenyl]hydrazine
• CAS: 754177-30-5
• 化学式: C₁₂H₁₁FN₂O
• 分子量: 218.231
• InChiKey: VMCRZGHCIQMPGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1R,2S,5R)-Menthyl chloroformate 、 (4-(4-fluorophenoxy)phenyl)hydrazine 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以85 %的产率得到L-menthyl 2-(4-(4-fluorophenoxy)phenyl)hydrazine-1-carboxylate
  参考文献：
  名称：

  新型L-薄荷醇酰肼衍生物作为潜在漆酶抑制剂的合成及其抗真菌活性

  摘要：

  为了发现新型漆酶抑制剂作为潜在的杀菌剂，设计并合成了 26 种新型 L-薄荷醇酰肼衍生物。在体外抗真菌试验中，大多数目标化合物对核盘菌、禾谷镰刀菌和葡萄球菌表现出明显的抗真菌活性。特别是，化合物3b和3q对B. dothidea的EC 50分别为0.465和0.622 mg/L，接近于阳性化合物fluxapyroxad（EC 50 =0.322 mg/L）。扫描电子显微镜（SEM）分析表明，化合物3b可显着破坏B. dothidea的菌丝形态。苹果果实体内抗真菌实验表明， 3b表现出优异的保护和疗效。此外，在体外漆酶抑制实验中，3b表现出优异的抑制活性，IC 50值为2.08 μM，远强于阳性对照半胱氨酸和PMDD-5Y。这些结果表明，此类 L-薄荷醇衍生物可能成为发现漆酶靶向杀菌剂的有希望的先导。

  DOI：

  10.1002/cbdv.202300539

文献信息

• Indene derivatives useful in treating pain and inflammation
  申请人：TARO PHARMACEUTICALS INC.

  公开号：US11352367B2

  公开（公告）日：2022-06-07

  Compounds of formula (I): wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.

  式（I）化合物：其中，R1、R2、R3、R4a、R4b 和 R5 如本文所述，或其立体异构体、对映体或同系物或其混合物，或其药学上可接受的盐或溶液，以及其他化合物。这些化合物可用于治疗炎症和/或疼痛。还公开了包含本发明化合物的组合物，以及使用这些化合物治疗炎症和/或疼痛的方法。
• ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER
  申请人：Euro-Celtique S.A.

  公开号：EP1292577A2

  公开（公告）日：2003-03-19
• INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION
  申请人：AQUINOX PHARMACEUTICALS (CANADA) INC.

  公开号：US20210032264A1

  公开（公告）日：2021-02-04

  Compounds of formula (I): wherein, R 1 , R 2 , R 3 , R 4a , R 4b and R 5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain.
• [EN] ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES, AND THE USE THEREOF<br/>[FR] PYRAZOLES, TRIAZOLES ET TETRAZOLES A SUBSTITUTION ARYLE ET LEUR UTILISATION
  申请人：COCENSYS INC

  公开号：WO2001072714A2

  公开（公告）日：2001-10-04

  This invention relates to compounds having the Formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Het and R5 - R8 are set in the specification. The invention also is directed to the use of compounds of Formula (I) for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
• [EN] HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE GPR119 POUR LE TRAITEMENT D'UNE MALADIE
  申请人：KALYPSYS INC

  公开号：WO2009117421A2

  公开（公告）日：2009-09-24

  The present invention relates to compounds and methods which may be useful as inhibitors of GPR119 for the treatment or prevention of metabolic, cardiovascular, and metabolic diseases.